{"id":9168,"date":"2017-09-20T11:00:00","date_gmt":"2017-09-20T09:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/"},"modified":"2026-05-05T22:12:19","modified_gmt":"2026-05-05T20:12:19","slug":"valberedningen-i-irlab-utsedd","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/","title":{"rendered":"Valberedningen i IRLAB utsedd"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>Inf\u00f6r \u00e5rsst\u00e4mman 2018 har bolagets tre st\u00f6rsta \u00e4gare, eller \u00e4gargrupper, utsett ledam\u00f6ter till valberedningen. I valberedningen ing\u00e5r Bo Rydlinger, Erik Klinton och John D. Wakely samt styrelsens ordf\u00f6rande Anders Vedin. Valberedningen representerar tillsammans drygt 40 procent av aktier och r\u00f6ster i bolaget.<\/strong><\/div>\n<p>Enligt den instruktion f\u00f6r valberedning i IRLAB Therapeutics AB som antogs p\u00e5 \u00e5rsst\u00e4mman den 16 maj 2017 ska valberedningen, ut\u00f6ver styrelsens ordf\u00f6rande, best\u00e5 av representanter f\u00f6r de tre st\u00f6rsta aktie\u00e4garna, eller \u00e4gargrupperna, per den 31 augusti.<\/p>\n<p>Efter att de tre st\u00f6rsta \u00e4garna eller \u00e4gargrupperna utsett sina representanter best\u00e5r valberedningen av f\u00f6ljande ledam\u00f6ter:<\/p>\n<ul>\n<li>Bo Rydlinger, m\u00e5ng\u00e5rig erfarenhet fr\u00e5n bank- och investeringsverksamhet, utsedd av en \u00e4gargrupp som representerar drygt 17 procent av aktier och r\u00f6ster,<\/li>\n<li>Erik Klinton, advokat med inriktning mot skatter\u00e4tt, utsedd av en \u00e4gargrupp best\u00e5ende av bolagets grundare som representerar drygt 13 procent av aktier och r\u00f6ster,<\/li>\n<li>John D. Wakely, verksam i bl a Storbritannien och med l\u00e5ng erfarenhet fr\u00e5n internationell finansmarknad, utsedd av Sievert Larsson Scholarship Foundation som \u00e4ger 10 procent av aktier och r\u00f6ster samt<\/li>\n<li>Anders Vedin, styrelsens ordf\u00f6rande i IRLAB Therapeutics AB.<\/li>\n<\/ul>\n<p>Information om valberedningens arbete samt instruktionen till valberedningen \u00e5terfinns p\u00e5 bolagets hemsida <a href=\"http:\/\/www.irlab.se\/corporate-governance\/nomination-committee\/\" rel=\"nofollow\">www.irlab.se\/corporate-governance\/nomination-committee\/<\/a>. Valberedningens f\u00f6rslag kommer att presenteras i kallelsen till \u00e5rsst\u00e4mman 2018 samt p\u00e5 bolagets hemsida, <a href=\"http:\/\/www.irlab.se\" rel=\"nofollow\">www.irlab.se<\/a>.<\/p>\n<p><span>Aktie\u00e4gare som vill l\u00e4mna f\u00f6rslag till valberedningen kan kontakta valberedningen p\u00e5 bolagets adress eller e-post &#8211; <a href=\"mailto:info@irlab.se\" rel=\"nofollow\">info@irlab.se<\/a>. F\u00f6r att ge valberedningen m\u00f6jlighet att beakta ett f\u00f6rslag m\u00e5ste det ha inkommit till valberedningen i god tid f\u00f6re \u00e5rsst\u00e4mman, dock senast den 31 januari 2018.<\/span><\/p>\n<div class=\"mfn-footer\">\n<p><strong>F\u00f6r mer information<\/strong><\/p>\n<p>Anders Vedin, styrelseordf\u00f6rande<br \/>Tel: +46 70 876 15 70<br \/>E-post: <a href=\"mailto:anders.vedin@irlab.se\" rel=\"nofollow\">anders.vedin@irlab.se<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Inf\u00f6r \u00e5rsst\u00e4mman 2018 har bolagets tre st\u00f6rsta \u00e4gare, eller \u00e4gargrupper, utsett ledam\u00f6ter till valberedningen. I valberedningen ing\u00e5r Bo Rydlinger, Erik Klinton och John D. Wakely samt styrelsens ordf\u00f6rande Anders Vedin. Valberedningen representerar tillsammans drygt 40 procent av aktier och r\u00f6ster i bolaget.<\/p>\n","protected":false},"template":"","class_list":["post-9168","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-ci-nomination_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Valberedningen i IRLAB utsedd - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valberedningen i IRLAB utsedd - IRLAB\" \/>\n<meta property=\"og:description\" content=\"Inf\u00f6r \u00e5rsst\u00e4mman 2018 har bolagets tre st\u00f6rsta \u00e4gare, eller \u00e4gargrupper, utsett ledam\u00f6ter till valberedningen. I valberedningen ing\u00e5r Bo Rydlinger, Erik Klinton och John D. Wakely samt styrelsens ordf\u00f6rande Anders Vedin. Valberedningen representerar tillsammans drygt 40 procent av aktier och r\u00f6ster i bolaget.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-05T20:12:19+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/\",\"url\":\"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/\",\"name\":\"Valberedningen i IRLAB utsedd - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2017-09-20T09:00:00+00:00\",\"dateModified\":\"2026-05-05T20:12:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Valberedningen i IRLAB utsedd\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valberedningen i IRLAB utsedd - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/","og_locale":"sv_SE","og_type":"article","og_title":"Valberedningen i IRLAB utsedd - IRLAB","og_description":"Inf\u00f6r \u00e5rsst\u00e4mman 2018 har bolagets tre st\u00f6rsta \u00e4gare, eller \u00e4gargrupper, utsett ledam\u00f6ter till valberedningen. I valberedningen ing\u00e5r Bo Rydlinger, Erik Klinton och John D. Wakely samt styrelsens ordf\u00f6rande Anders Vedin. Valberedningen representerar tillsammans drygt 40 procent av aktier och r\u00f6ster i bolaget.","og_url":"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/","og_site_name":"IRLAB","article_modified_time":"2026-05-05T20:12:19+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/","url":"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/","name":"Valberedningen i IRLAB utsedd - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2017-09-20T09:00:00+00:00","dateModified":"2026-05-05T20:12:19+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"Valberedningen i IRLAB utsedd"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}